1. Home
  2. CDNA vs MDXG Comparison

CDNA vs MDXG Comparison

Compare CDNA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$20.58

Market Cap

712.2M

Sector

Health Care

ML Signal

HOLD

Logo MiMedx Group Inc

MDXG

MiMedx Group Inc

HOLD

Current Price

$7.21

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
MDXG
Founded
1998
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
712.2M
1.0B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CDNA
MDXG
Price
$20.58
$7.21
Analyst Decision
Buy
Buy
Analyst Count
7
1
Target Price
$26.00
$12.00
AVG Volume (30 Days)
778.5K
755.0K
Earning Date
11-04-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.22
0.27
Revenue
$357,998,000.00
$393,442,000.00
Revenue This Year
$14.11
$19.13
Revenue Next Year
$12.00
$2.11
P/E Ratio
$16.30
$26.86
Revenue Growth
14.46
14.77
52 Week Low
$10.96
$5.79
52 Week High
$25.95
$9.71

Technical Indicators

Market Signals
Indicator
CDNA
MDXG
Relative Strength Index (RSI) 71.98 56.44
Support Level $18.36 $6.62
Resistance Level $19.95 $7.06
Average True Range (ATR) 0.86 0.23
MACD 0.19 0.05
Stochastic Oscillator 99.42 91.11

Price Performance

Historical Comparison
CDNA
MDXG

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: